Organic Letters
Letter
B. V.; Prabhu, K. R. J. Org. Chem. 2014, 79, 9655. (e) Varun, B. V.; Sood,
A.; Prabhu, K. R. RSC Adv. 2014, 4, 60798.
Scheme 7. Possible Mechanism
(4) For selected reviews about outline of pyrazole synthesis from β-
diketones and their pharmaceutical application, see: (a) Kumar, K. A.;
Jayaroopa, P. Inter. J. Pharm. Technol. Res. 2014, 5, 1473. (b) Chauhan,
M.; Kumar, R. Bioorg. Med. Chem. 2013, 21, 5657. (c) Kumar, V.; Kaur,
K.; Gupta, G. K.; Sharma, A. K. Eur. J. Med. Chem. 2013, 69, 735.
(d) Kasiotis, K. M.; Tzanetou, E. N.; Haroutounian, S. A. Front. Chem.
2014, 2, 1. (e) Pal, D.; Saha, S.; Singh, S. Int. J. Pharm. Pharm. Sci. 2012,
4, 98. For synthesis of pyrazole from β-diketones, see: (f) Knorr, L. Ber.
1883, 16, 2587. (g) Fustero, S.; Roman, R.; Sanz-Cervera, J. F.; Simon-
Fuentes, A. X.; Cunat, A. C.; Villanova, S.; Murguia, M. J. Org. Chem.
2008, 73, 3523. (h) Kost, A. N.; Grandberg, I. I. Adv. Heterocycl. Chem.
1966, 6, 347. (i) Gerstenberger, B. S.; Rauckhorst, M. R.; Starr, J. T. Org.
Lett. 2009, 11, 2097.
(5) For oxazole synthesis from β-diketones and biological activity, see:
(a) Wan, C.; Zhang, J.; Wang, S.; Fan, J.; Wang, Z. Org. Lett. 2010, 12,
2338 and references therein. (b) Turchi, I. J.; Dewar, M. J. S. Chem. Rev.
1975, 75, 389. (c) Turchi, I. J. Ind. Eng. Chem. Prod. Res. Dev. 1981, 20,
32. For diazapine synthesis and biological activity, see: (d) Polshettiwar,
V.; Varma, R. S. Tetrahedron Lett. 2008, 49, 397 and references therein.
(e) Eweas, A. F.; Allam, G.; Abuelsaad, A. S. A.; ALGhamdi, A. H.;
Maghrabi, I. A. Bioorg. Chem. 2013, 46, 17 and references therein. For
isoxazole: (f) Pinho e Melo, M. V. D. T. Curr. Org. Chem. 2005, 9, 925.
ASSOCIATED CONTENT
* Supporting Information
Experimental procedure, characterization data of all the
compounds, spectral data. The Supporting Information is
■
S
(6) (a) Dengiz, C.; Çalısķ an, R.; Balci, M. Tetrahedron Lett. 2012, 53,
550. (b) Christoffers, J.; Kreidler, B.; Unger, S.; Frey, W. Eur. J. Org.
Chem. 2003, 2003, 2845. (c) Kalaitzakis, D.; Rozzell, J. D.; Smonou, I.;
Kambourakis, S. Adv. Synth. Catal. 2006, 348, 1958. (d) Shen, Q.;
Huang, W.; Wang, J.; Zhou, X. Org. Lett. 2007, 9, 4491. (e) Smith, A. B.
I.; Atasoylu, O.; Beshore, D. C. Synlett 2009, 2009, 2643. (f) Ding, R.;
AUTHOR INFORMATION
Corresponding Author
■
Katebzadeh, K.; Roman, L.; Bergquist, K. E.; Lindstrom, U. M. J. Org.
̈
Chem. 2005, 71, 352.
(7) (a) Wu, F.; Li, H.; Hong, R.; Deng, L. Angew. Chem., Int. Ed. 2006,
45, 947. (b) Okino, T.; Hoashi, Y.; Furukawa, T.; Xu, X.; Takemoto, Y. J.
Am. Chem. Soc. 2005, 127, 119. (c) Hiroi, K.; Nishida, M.; Nakayama, A.;
Nakazawa, K.; Fujii, E.; Sato, S. Chem. Lett. 1979, 8, 969. (d) Jereb, M.;
Togni, A. Org. Lett. 2005, 7, 4041.
(8) US patent; Maender, O. W.; Morita, E. EP0029719A1, 1982.
(9) (a) Yoshida, Z.; Ogoshi, H.; Tokumitsu, T. Tetrahedron 1970, 26,
2987. (b) Rashid, M. A.; Reinke, H.; Langer, P. Tetrahedron Lett. 2007,
48, 2321. (c) D’Amico, J. J.; Harman, M. W.; Cooper, R. H. J. Am. Chem.
Soc. 1957, 79, 5270. (d) D’Amico, J. J. J. Org. Chem. 1961, 26, 3436.
(10) (a) Ogura, K.; Sanada, K.; Takahashi, K.; Iida, H. Tetrahedron Lett.
1982, 23, 4035. (b) Fujisawa, T.; Hata, K.; Kojima, T. Chem. Lett. 1973,
2, 287. (c) Mukaiyama, T.; Kobayashi, S.; Kumamoto, T. Tetrahedron
Lett. 1970, 11, 5115. (d) Asaoka, M.; Miyke, K.; Takei, H. Bull. Chem.
Soc. Jpn. 1978, 3008. (e) Torii, S.; Tanaka, H.; Okumoto, H. Bull. Chem.
Soc. Jpn. 1979, 269. (f) Wenschuh, E.; Hesselbarth, F. Phosphorus, Sulfur,
Silicon Relat. Elem. 1991, 59, 133.
Notes
The authors declare no competing financial interest.
ACKNOWLEDGMENTS
■
The financial support from IISc, and DST (SERB), New-Delhi is
gratefully acknowledged. Authors thank Dr. A. R. Ramesha (RL
Fine Chem) for useful discussions. B.V.V. thanks CSIR for a
senior fellowship.
REFERENCES
■
(1) (a) Frausto da Silva, J. R.; Williams, R. J. P. The Biological Chemistry
̀
of the Elements; Oxford University Press: New York, 2001. (b) Block, E.
Reactions of Organosulfur Compounds; Academic Press: 1978. (c) Orga-
nosulfur compound. Encyclopædia Britannica [Online]; Encyclopædia
May 13, 2015). (d) Procopiou, P. A.; Biggadike, K.; English, A. F.;
Farrell, R. M.; Hagger, G. N.; Hancock, A. P.; Haase, M. V.; Irving, W. R.;
Sareen, M.; Snowden, M. A.; Solanke, Y. E.; Tralau-Stewart, C. J.;
Walton, S. E.; Wood, J. A. J. Med. Chem. 2001, 44, 602.
(11) Zou, L.-H.; Priebbenow, D. L.; Wang, L.; Mottweiler, J.; Bolm, C.
Adv. Synth. Catal. 2013, 355, 2558.
(12) An aqueous solution of HClO4 (70% in water) is stable, harmless,
and less expensive.
(13) See the Supporting Information for details.
(2) For drug molecules containing chiral sulphur and thioether, see:
(a) Clayden, J.; MacLellan, P. Beilstein J. Org. Chem. 2011, 7, 582. For
organosulfur compounds related to cancer and cardiovascular disease,
see: (b) Vazquez-Prieto, M. A.; Miatello, R. M. Mol. Aspects Med. 2010,
31, 540. (c) Omar, S. H.; Al-Wabel, N. A. Saudi Pharm. J. 2010, 18, 51.
(d) Sahu, S. C. J. Environ. Sci. Health, Part C 2002, 20, 61. (e) Sulphur-
Containing Drugs and Related Organic Compounds; Damani, L. A., Ed.;
Wiley: New York, 1989. (f) Kucera, G. L.; Goff, C. L.; Iyer, N.; Morris-
Natschke, S.; Ishaq, K. S.; Wyrick, S. D.; Fleming, R. A.; Kucera, L. S.
AntiViral Res. 2001, 50, 129. (g) Gendron, F.-P.; Halbfinger, E.; Fischer,
(14) However, a similar reaction of oxazolidine-2-thione under optimal
conditions formed a complex mixture.
(15) Yu, B.; Liu, A.-H.; He, L.-N.; Li, B.; Diao, Z.-F.; Li, Y.-N. Green
Chem. 2012, 14, 957.
(16) Our attempts to detect the formation of key intermediate 1
(Scheme 7) by NMR or MS was not successful (see the Supporting
Information for further details).
B.; Duval, M.; D’Orlea
43, 2239.
́
ns-Juste, P.; Beaudoin, A. R. J. Med. Chem. 2000,
(3) See the following reviews and references therein: (a) Chauhan, P.;
Mahajan, S.; Enders, D. Chem. Rev. 2014, 114, 8807. (b) Trost, B. M.
Chem. Rev. 1978, 78, 363. For other relative work from our laboratory,
see: (c) Varun, B. V.; Prabhu, K. R. RSC Adv. 2013, 3, 3079. (d) Varun,
D
Org. Lett. XXXX, XXX, XXX−XXX